Four research-grade peptides target distinct cognitive pathways — from BDNF/NGF upregulation and GABA-A modulation to structural synaptogenesis and gut-brain axis repair. This guide covers mechanisms, evidence, dosing, and stacking protocols for Semax, Selank, Dihexa, and BPC-157.
Research purposes only. All compounds discussed are research chemicals, not FDA-approved medications. Cognitive peptides are not approved for human use in the United States. This content is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.
Cognitive enhancement research has identified four primary peptide mechanisms: neurotrophic factor upregulation (BDNF/NGF via Semax), GABAergic modulation (Selank), structural synaptogenesis (Dihexa via HGF/c-Met), and neurotransmitter rebalancing via the gut-brain axis (BPC-157). These mechanisms are largely complementary — targeting different aspects of the same cognitive performance system.
Semax and Selank have the strongest human evidence base — both have been studied in Russian Phase 2/3 clinical trials and are approved as prescription nootropics in Russia. Dihexa has remarkable preclinical potency but essentially no human clinical data. BPC-157 bridges cognitive and systemic health through the gut-brain axis and dopaminergic pathway repair.
Pathway: BDNF/NGF → Prefrontal cortex & hippocampus
Effect: Focus, memory, stress resilience
Pathway: GABA-A modulation → Anxiolytic nootropic
Effect: Anxiety reduction, working memory
Pathway: HGF/c-Met → Synaptogenesis, LTP
Effect: Structural synaptic repair, neurodegeneration
Pathway: Dopamine D1/D2 repair → Gut-brain axis
Effect: Neurotransmitter rebalancing, neuroprotection
Comparative overview of mechanism, dosing, and evidence strength for each compound.
| Compound | Primary Mechanism | Cognitive Benefit | Typical Dose | Evidence | Strength |
|---|---|---|---|---|---|
| Semax | BDNF/NGF upregulation, dopamine/serotonin modulation, HPA axis | Focus, memory consolidation, verbal fluency, stress resilience | 200–600 mcg intranasal, daily (2–4 week cycles) | Phase 2/3 RCTs (stroke, ADHD, optic nerve disease — Russia) | Strong (human trials, approved in Russia) |
| Selank | GABA-A modulation, BDNF upregulation, enkephalin stabilization | Anxiety reduction, working memory, executive function under stress | 250–500 mcg intranasal, daily (2–4 week cycles) | Phase 2 RCTs (GAD, mixed anxiety-depressive disorder — Russia) | Strong (human trials, approved in Russia) |
| Dihexa | HGF/c-Met signaling, synaptogenesis, dendritic spine formation, LTP | Structural synaptic repair, neurodegeneration reversal, LTP enhancement | 1–10 mg SubQ or transdermal (research dosing only) | Preclinical (extensive); no human clinical trials | Preclinical only |
| BPC-157 | Dopamine D1/D2 repair, serotonin rebalancing, NF-κB inhibition, gut-brain axis | Neurotransmitter rebalancing, neuroprotection, cognitive fog reduction | 250–500 mcg SubQ or oral, daily | Preclinical (extensive); Phase 1 safety | Moderate (preclinical + Phase 1) |
ACTH(4-7) analogue · Intranasal · Approved in Russia
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) sequence. It is the most studied cognitive peptide with human clinical trial data, having been evaluated in Russian Phase 2/3 trials for ischemic stroke recovery, ADHD, optic nerve disease, and cognitive impairment. Its primary mechanism is upregulation of BDNF and NGF in the prefrontal cortex and hippocampus — the two brain regions most critical for working memory, executive function, and long-term potentiation.
Beyond neurotrophic effects, Semax modulates dopamine and serotonin release, reduces neuroinflammation (IL-6, TNF-α suppression), and enhances HPA axis stress resilience. Effects on focus and verbal fluency are typically reported within 30–60 minutes of intranasal administration. Standard research dosing is 200–600 mcg intranasally, 1–2× daily, in 2–4 week cycles.
Route
Intranasal
Dose
200–600 mcg/day
Cycle
2–4 weeks on/off
Onset
30–60 min
Tuftsin analogue · Intranasal · Approved in Russia
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of the endogenous neuropeptide tuftsin with an added stabilizing sequence. It modulates GABA-A receptor activity, producing anxiolytic effects without the sedation, dependence, or cognitive blunting associated with benzodiazepines. Selank also upregulates BDNF expression and stabilizes enkephalin degradation — endogenous opioid peptides involved in mood regulation and memory consolidation.
Its most clinically relevant application is anxiety-driven cognitive impairment — a condition where anxiety disrupts working memory, executive function, and verbal fluency. Russian Phase 2 trials have studied Selank for generalized anxiety disorder and mixed anxiety-depressive disorder. Unlike Semax, Selank does not typically increase anxiety at higher doses, making it the preferred choice when the cognitive impairment has an anxiety component.
Route
Intranasal
Dose
250–500 mcg/day
Cycle
2–6 weeks on/off
Dependence
None reported
Angiotensin IV derivative · SubQ / Transdermal · Research only
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide derived from angiotensin IV that activates HGF (hepatocyte growth factor) / c-Met receptor signaling — a pathway critical for synaptogenesis, dendritic spine formation, and long-term potentiation (LTP). Unlike Semax and Selank, which primarily modulate neurotransmitter systems, Dihexa promotes structural synaptic repair and new synapse formation at the cellular level.
In animal models, Dihexa has demonstrated cognitive benefits approximately 10 million times more potent than BDNF on a molar basis — a remarkable preclinical finding. It is being studied for Alzheimer's disease, traumatic brain injury, and age-related cognitive decline. However, human clinical trial data is essentially absent, and the long-term safety profile in humans is unknown. Dihexa should be used with extreme caution; it is strictly a research compound.
Caution: Dihexa has no human clinical trial safety data. Its potency and mechanism (permanent synaptogenesis) raise theoretical concerns about uncontrolled synaptic growth. Use only under research conditions with full awareness of the unknown risk profile.
Route
SubQ / Transdermal
Dose
1–10 mg (research)
Cycle
6–8 weeks max
Human Data
None
Gastric pentadecapeptide · SubQ or Oral · Research only
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protective gastric protein. Its cognitive relevance stems from three mechanisms: dopamine D1/D2 receptor repair (restoring dopaminergic signaling after injury or chronic stress), serotonin rebalancing (particularly relevant for post-SSRI discontinuation), and gut-brain axis repair (reducing systemic inflammation that drives cognitive fog via the vagus nerve and enteric nervous system).
BPC-157 has shown neuroprotective effects in animal models of traumatic brain injury, stroke, and drug-induced neurotoxicity (amphetamine, opioid, and SSRI-induced dopamine system damage). It is typically used as a foundation compound in cognitive stacks — providing systemic support while Semax or Selank provide the primary nootropic effect. Oral administration is effective for gut-brain axis effects; subcutaneous for systemic and CNS effects.
Route
SubQ or Oral
Dose
250–500 mcg/day
Cycle
4–8 weeks on/off
Onset
1–2 weeks
Research-informed protocols for different cognitive goals. These are not medical recommendations.
Semax upregulates BDNF/NGF and dopamine for acute focus and memory consolidation. BPC-157 provides gut-brain axis support and dopaminergic pathway repair as a foundation. Best for cognitive performance under normal stress conditions.
Selank's GABA-A modulation reduces anxiety-driven cognitive impairment while Semax provides activating nootropic effects. BPC-157 supports the gut-brain axis and serotonin rebalancing. The Selank/Semax combination is the most studied cognitive peptide stack in Russian research.
Dihexa provides structural synaptic repair via HGF/c-Met signaling. Semax maintains BDNF/NGF upregulation and neurotransmitter support. BPC-157 provides neuroprotection and gut-brain axis repair. This stack is targeted at TBI recovery, age-related cognitive decline, or post-neurotoxic states. Dihexa should be used cautiously given limited human safety data.
Match your primary cognitive goal to the most appropriate compound or stack.
| Primary Goal | Primary Compound | Secondary / Stack | Notes |
|---|---|---|---|
| Acute focus and memory for cognitive work | Semax | BPC-157 (gut-brain foundation) | Best activating nootropic; use 200–400 mcg intranasal AM |
| Anxiety-driven cognitive impairment | Selank | Semax (add if anxiety is controlled) | GABA-A modulation without sedation or dependence |
| High-stress cognitive performance | Selank + Semax stack | BPC-157 (foundation) | Complementary anxiolytic + activating nootropic combination |
| TBI recovery or structural synaptic repair | Dihexa | Semax + BPC-157 | HGF/c-Met synaptogenesis; use cautiously — limited human data |
| Cognitive fog from gut dysbiosis or chronic inflammation | BPC-157 | Semax (add after 2–4 weeks) | Gut-brain axis repair first; dopaminergic rebalancing |
| Post-SSRI discontinuation cognitive symptoms | BPC-157 | Selank (anxiety component) | Serotonin rebalancing and GABA-A modulation |
| Age-related cognitive decline / neurodegeneration | Dihexa + Semax | BPC-157 (neuroprotection) | Synaptogenesis + BDNF/NGF upregulation; long-term protocol |
| ADHD-like focus and executive function | Semax | Selank (if anxiety component) | Dopamine modulation; studied in Russian ADHD trials |
The most researched peptides for cognitive enhancement are Semax (BDNF/NGF upregulation, dopamine modulation), Selank (GABA-A modulation, anxiolytic nootropic), Dihexa (HGF/c-Met signaling, synaptogenesis), and BPC-157 (dopaminergic and serotonergic pathway repair, gut-brain axis). Semax is best for acute focus and memory consolidation; Selank for anxiety-driven cognitive impairment; Dihexa for structural synaptic repair and neurodegeneration; BPC-157 for gut-brain axis restoration and neurotransmitter rebalancing after injury or chronic stress.
Semax is a synthetic heptapeptide analogue of ACTH(4-7) that upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the prefrontal cortex and hippocampus. It also modulates dopamine and serotonin release, enhances HPA axis stress resilience, and reduces neuroinflammation via IL-6 and TNF-α suppression. In Russian clinical trials, Semax has been studied for ischemic stroke recovery, ADHD, and optic nerve disease. Typical intranasal dosing is 200–600 mcg/day in 2–4 week cycles. Effects on focus, working memory, and verbal fluency are reported within 30–60 minutes of intranasal administration.
Selank is a synthetic analogue of the endogenous neuropeptide tuftsin (Thr-Lys-Pro-Arg) with an added Gly-Glu-Thr sequence for stability. It modulates GABA-A receptor activity (anxiolytic effect), upregulates BDNF expression, and stabilizes enkephalin degradation (endogenous opioid peptides involved in mood and memory). Unlike benzodiazepines, Selank does not cause dependence, sedation, or cognitive blunting. It is particularly effective for anxiety-driven cognitive impairment — where anxiety disrupts working memory and executive function. Russian clinical trials have studied it for generalized anxiety disorder and mixed anxiety-depressive disorder.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide derived from angiotensin IV that activates HGF (hepatocyte growth factor) / c-Met receptor signaling — a pathway critical for synaptogenesis, dendritic spine formation, and long-term potentiation (LTP). Unlike Semax and Selank which primarily modulate neurotransmitter systems, Dihexa promotes structural synaptic repair and new synapse formation. In animal models, Dihexa has shown cognitive benefits approximately 10 million times more potent than BDNF. It is being studied for Alzheimer's disease, traumatic brain injury, and age-related cognitive decline. Human data is very limited; it is a research compound only.
BPC-157 supports cognitive function primarily through the gut-brain axis and dopaminergic/serotonergic pathway repair. It upregulates dopamine D1/D2 receptor sensitivity, restores serotonin balance after SSRI discontinuation, and reduces neuroinflammation via NF-κB inhibition. BPC-157 has shown neuroprotective effects in animal models of traumatic brain injury, stroke, and drug-induced neurotoxicity (including amphetamine and opioid-induced dopamine system damage). Its gut-brain axis effects are particularly relevant for cognitive fog associated with gut dysbiosis, leaky gut, and chronic inflammation. It is often stacked with Semax or Selank for comprehensive cognitive support.
The most commonly researched cognitive peptide stack combines Semax (BDNF/NGF upregulation, acute focus) with Selank (GABA-A modulation, anxiety reduction). This stack addresses both the excitatory (Semax) and inhibitory (Selank) arms of cognitive function, making it particularly effective for high-stress cognitive demands. For structural synaptic repair and neurodegeneration, Dihexa can be added in short cycles. BPC-157 is often included as a foundation for gut-brain axis support and neurotransmitter rebalancing. Semax and Selank are typically used intranasally; BPC-157 subcutaneously or orally; Dihexa subcutaneously.
Semax and Selank have the strongest human safety data — both have been studied in Russian clinical trials and are approved in Russia as prescription nootropics. Semax has been used in stroke rehabilitation and ADHD research with a favorable safety profile at standard doses (200–600 mcg intranasal). Selank shows no dependence, withdrawal, or cognitive blunting in clinical studies. Dihexa has very limited human safety data and should be used with extreme caution; it is a research compound with no clinical trial safety record in humans. BPC-157 has extensive preclinical safety data and Phase 1 human safety data. None of these are FDA-approved.
Semax and Selank are complementary rather than competing nootropics. Semax is primarily activating — it upregulates BDNF/NGF, enhances dopamine/serotonin release, and improves focus, memory consolidation, and verbal fluency. It can increase anxiety in some users at higher doses. Selank is primarily calming — it modulates GABA-A receptors, reduces anxiety, and improves cognitive performance under stress without sedation. For pure focus and memory, Semax is preferred. For anxiety-driven cognitive impairment or high-stress environments, Selank is preferred. Many researchers stack both for a balanced nootropic effect. See the full Selank vs Semax comparison for a detailed head-to-head analysis.
Purgo Labs supplies ≥99% purity Semax, Selank, and BPC-157 with third-party COA verification. Use code HEALTH for 15% off.
Shop Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.